Pharmacokinetic and pharmacodynamic characteristics of HFA and CFC pMDI formulations of budesonide
K. Clearie, P. Williamson, K. Meldrum, M. Gillen, L. G. Carlsson, M. Carlholm, J. Ekelund, B. Lipworth (Dundee, United Kingdom; Wilmington, United States Of America; Lund, Sweden)
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Session: Drug delivery and pharmacokinetics I
Session type: E-Communication Session
Number: 2023
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Clearie, P. Williamson, K. Meldrum, M. Gillen, L. G. Carlsson, M. Carlholm, J. Ekelund, B. Lipworth (Dundee, United Kingdom; Wilmington, United States Of America; Lund, Sweden). Pharmacokinetic and pharmacodynamic characteristics of HFA and CFC pMDI formulations of budesonide. Eur Respir J 2010; 36: Suppl. 54, 2023
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Pharmacokinetic evaluation of two HFA pMDI formulations of salmeterol xinafoate administered through a spacer in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Evaluation of the systemic pharmacodynamic effects of two HFA formulations of Salmeterol xinafoate/Fluticasone propionate HFA pMDI 25/250 mcg Source: International Congress 2017 – Inhalers and their use Year: 2017
Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Systemic activity of beclometasone dipropionate HFA and CFC formulations in metered dose inhalers assessed by knemometry Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Budesonide pharmacokinetics and systemic effects at steady state via HFA pMDI, CFC pMDI and Turbuhaler® in healthy volunteers Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Efficacy and safety of new formulation of fluticasone propionate/salmeterol delivered via a HFA pMDI inhaler in patients with asthma Source: Virtual Congress 2020 – Asthma inhalers: devices and adherence studies Year: 2020
A new nonultra fine BDP HFA 134a formulation: clinical equivalence of efficacy and safety versus CFC formulation Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
Pharmacokinetics and pharmacodynamics of beclomethasone dipropionate and formoterol combination after inhalation using a new dry powder inhaler Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007
The novel budesonide HFA pMDI is clinically comparable to the conventional budesonide CFC pMDI in paediatric patients with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005
Comparison of the efficacy and safety of budesonide administered via Clickhaler® or Turbuhaler® Source: Eur Respir J 2003; 22: Suppl. 45, 311s Year: 2003
Efficacy of ipratropium bromide/ fenoterol hydrobromide HFA and CFC propellant inhalers in patients with COPD Source: Eur Respir J 2003; 22: Suppl. 45, 52s Year: 2003
Pharmacokinetics and pharmacodynamics of a new beclomethasone dipropionate and formoterol CFC-free fixed combination in healthy volunteers Source: Eur Respir J 2006; 28: Suppl. 50, 667s Year: 2006
Ipratropium bromide HFA propellant inhaler has equivalent safety and efficacy to the marketed CFC propellant inhaler in bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
Pharmaceutical development of salmeterol HFA metered dose inhaler Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004
Systemic effects and pharmacokinetics of a new CFC-free metered dose inhaler of beclomethasone dipropionate following multiple dosing in asthmatic patients Source: Eur Respir J 2005; 26: Suppl. 49, 180s Year: 2005
Physicochemical compatibility of ipratropium, albuterol and fluticasone nebulizer solutions Source: Eur Respir J 2006; 28: Suppl. 50, 211s Year: 2006
A comparative study of the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of salmeterol HFA and CFC MDI inhalers in healthy subjects Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004
Pharmacokinetic and pharmacodinamic effect of AeroChamber Plus spacer on the Extrafine beclometasone dipropionate plus formoterol combination (200/6 µg) Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
PK and PD of a new beclomethasone dipropionate and formoterol CFC-free fixed combination Source: Eur Respir J 2007; 30: Suppl. 51, 358s Year: 2007
Budesonide HFA pMDI is pharmacokinetically and clinically comparable with budesonide CFC pMDI in healthy volunteers, and in adults and children with asthma Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005